Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines

Omi,Kan; Matsuo,Yoichi; Ueda,Goro; Aoyama,Yoshinaga; Kato,Tomokatsu; Hayashi,Yuichi; Imafuji,Hiroyuki; Saito,Kenta; Tsuboi,Ken; Morimoto,Mamoru; Ogawa,Ryo; Takahashi,Hiroki; Takiguchi,Shuji

doi:10.3892/or.2021.8006

Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines

Authors:
- Kan Omi
- Yoichi Matsuo
- Goro Ueda
- Yoshinaga Aoyama
- Tomokatsu Kato
- Yuichi Hayashi
- Hiroyuki Imafuji
- Kenta Saito
- Ken Tsuboi
- Mamoru Morimoto
- Ryo Ogawa
- Hiroki Takahashi
- Shuji Takiguchi
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan
Published online on: March 9, 2021 https://doi.org/10.3892/or.2021.8006
Article Number: 55
Copyright: © Omi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer (PaCa) is one of the most aggressive types of cancer. Thus, the development of new and more effective therapies is urgently required. Escin, a pentacyclic triterpenoid from the horse chestnut, has been reported to exhibit antitumor potential by reducing cell proliferation and blocking the nuclear factor‑κB (NF‑κB) signaling pathway in several types of cancer. Our previous study reported that NF‑κB enhanced the secretion of interleukin (IL)‑8 and vascular endothelial growth factor (VEGF), thereby inducing angiogenesis in PaCa cell lines. In the present study, it was examined whether escin inhibited angiogenesis by blocking NF‑κB activation in PaCa. It was initially confirmed that escin, at concentrations >10 µM, significantly inhibited the proliferation of several PaCa cell lines. Next, using immunocytochemical staining, it was found that escin inhibited the nuclear translocation of NF‑κB. Furthermore, ELISA confirmed that NF‑κB activity in the escin‑treated PaCa cells was significantly inhibited and reverse transcription‑quantitative PCR showed that the mRNA expression levels of tumor necrosis factor‑α‑induced IL‑8 and VEGF were significantly suppressed following escin treatment in the PaCa cell lines. ELISA also showed that escin decreased the secretion of IL‑8 and VEGF from the PaCa cells. Furthermore, tube formation in immortalized human endothelial cells was inhibited following incubation with the supernatants from escin‑treated PaCa cells. These results indicated that escin inhibited angiogenesis by reducing the secretion of IL‑8 and VEGF by blocking NF‑κB activity in PaCa. In conclusion, escin could be used as a novel molecular therapy for PaCa.

View Figures

View References

1	National Cancer Center Japan, Center for Cancer Control and Information Services. 2020, https://ganjoho.jp/reg_stat/statistics/stat/summary.html
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Rawla P, Sunkara T and Gaduputi V: Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol. 10:10–27. 2019. View Article : Google Scholar : PubMed/NCBI
4	Cao H, Le D and Yang LX: Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Res. 33:1785–1791. 2013.PubMed/NCBI
5	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
6	Von Hoff DD, Ervin T, Arena FP, hiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
7	Torphy RJ, Fujiwara Y and Schulick RD: Pancreatic cancer treatment: Better, but a long way to go. Surg Today. 50:1117–1125. 2020. View Article : Google Scholar : PubMed/NCBI
8	Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, et al: Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 35 (Suppl 1):S224–S243. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gupta SC, Kim JH, Prasad S and Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kwak H, An H, Alam MB, Choi WS, Lee SY and Lee SH: Inhibition of migration and invasion in melanoma cells by β-escin via the ERK/NF-κB signaling pathway. Biol Pharm Bull. 41:1606–1610. 2018. View Article : Google Scholar : PubMed/NCBI
11	Çiftçi GA, Işcan A and Kutlu M: Escin reduces cell proliferation and induces apoptosis on glioma and lung adenocarcinoma cell lines. Cytotechnology. 67:893–904. 2015. View Article : Google Scholar : PubMed/NCBI
12	Harford-Wright E, Bidère N and Gavard J: β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability. Oncotarget. 7:66865–66879. 2016. View Article : Google Scholar : PubMed/NCBI
13	Rimmon A, Vexler A, Berkovich L, Earon G, Ron I and Lev-Ari S: Escin chemosensitizes human pancreatic cancer cells and inhibits the nuclear factor-kappaB signaling pathway. Biochem Res Int. 2013:2517522013. View Article : Google Scholar : PubMed/NCBI
14	Zhu J, Yu W, Liu B, Wang Y, Shao J, Wang J, Xia K, Liang C, Fang W, Zhou C and Tao H: Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis. 8:e31132017. View Article : Google Scholar : PubMed/NCBI
15	Wang YW, Wang SJ, Zhou YN, Pan SH and Sun B: Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol. 138:785–797. 2012. View Article : Google Scholar : PubMed/NCBI
16	Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S and Aggarwal BB: Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol. 77:818–827. 2010. View Article : Google Scholar : PubMed/NCBI
17	Pramanik K, Makena M, Bhowmick K and Pandey M: Advancement of NF-κB signaling pathway: A novel target in pancreatic cancer. Int J Mol Sci. 19:38902018. View Article : Google Scholar
18	Matsuo Y, Sawai H, Ochi N, Yasuda A, Sakamoto M, Takahashi H, Funahashi H, Takeyama H and Guha S: Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig Dis Sci. 55:1167–1176. 2010. View Article : Google Scholar : PubMed/NCBI
19	Bussolino F, Mantovani A and Persico G: Molecular mechanisms of blood vessel formation. Trends Biochem Sci. 22:251–256. 1997. View Article : Google Scholar : PubMed/NCBI
20	Sosmitha G, Bano S, Javadi M, Lu F, Clarissa EH, Frank A, Kwang Seok A, Gautam S and Ajaikumar BK: Zerumbone as an anti-cancer agent. Molecules. 24:7342019. View Article : Google Scholar
21	Meteoglu I, Erdogdu IH, Meydan N, Erkus M and Barutca S: NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res. 27:532008. View Article : Google Scholar : PubMed/NCBI
22	Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW and Korc M: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 3:1309–1316. 1997.PubMed/NCBI
23	Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q and Xie K: Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res. 5:3711–3721. 1999.PubMed/NCBI
24	Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC and Xie K: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61:4143–4154. 2001.PubMed/NCBI
25	Saito K, Matsuo Y, Imafuji H, Okubo T, Maeda Y, Sato T, Shamoto T, Tsuboi K, Morimoto M, Takahashi H, et al: Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. Cancer Sci. 109:132–140. 2018. View Article : Google Scholar : PubMed/NCBI
26	Tsuboi K, Matsuo Y, Shamoto T, Shibata T, Koide S, Morimoto M, Guha S, Sung B, Aggarwal BB, Takahashi H and Takeyama H: Zerumbone inhibits tumor angiogenesis via NF-κB in gastric cancer. Oncol Rep. 31:57–64. 2014. View Article : Google Scholar : PubMed/NCBI
27	Bustin S: Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J Mol Endocrinol. 29:23–39. 2002. View Article : Google Scholar : PubMed/NCBI
28	Folkman J: Angiogenesis and angiogenesis inhibition: An overview. Exs. 79:1–8. 1997.PubMed/NCBI
29	Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR and Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53:4727–4735. 1993.PubMed/NCBI
30	Sawai H, Funahashi H, Okada Y, Matsuo Y, Sakamoto M, Yamamoto M, Takeyama H and Manabe T: Interleukin-1alpha enhances IL-8 secretion through p38 mitogen-activated protein kinase and reactive oxygen species signaling in human pancreatic cancer cells. Med Sci Monit. 11:BR343–BR350. 2005.PubMed/NCBI
31	Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
32	Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L and Xie K: NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 108:181–188. 2004. View Article : Google Scholar : PubMed/NCBI
33	Arlt A and Schäfer H: NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther. 40:336–347. 2002. View Article : Google Scholar : PubMed/NCBI
34	Sebens S, Arlt A and Schäfer H: NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 177:151–164. 2008. View Article : Google Scholar : PubMed/NCBI
35	Holcomb B, Yip-Schneider M and Schmidt CM: The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas. 36:225–235. 2008. View Article : Google Scholar : PubMed/NCBI
36	Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
37	Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB and Sung B: Molecular targets of nutraceuticals derived from dietary spices: Potential role in suppression of inflammation and tumorigenesis. Exp Biol Med (Maywood). 234:825–849. 2009. View Article : Google Scholar : PubMed/NCBI
38	Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S and Aggarwal BB: Sesamin manifests chemopreventive effects through the suppression of NF-kappaB-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res. 8:751–761. 2010. View Article : Google Scholar : PubMed/NCBI
39	Yue Q, Gao G, Zou G, Yu H and Zheng X: Natural products as adjunctive treatment for pancreatic cancer: Recent trends and advancements. Biomed Res Int. 2017:84125082017. View Article : Google Scholar : PubMed/NCBI
40	Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 67:3853–3861. 2007. View Article : Google Scholar : PubMed/NCBI
41	Gallelli L: Escin: A review of its anti-edematous, anti-inflammatory, and venotonic properties. Drug Des Devel Ther. 13:3425–3437. 2019. View Article : Google Scholar : PubMed/NCBI
42	Li M, Lu C, Zhang L, Zhang J, Du Y, Duan S, Wang T and Fu F: Oral administration of escin inhibits acute inflammation and reduces intestinal mucosal injury in animal models. Evid Based Complement Alternat Med. 2015:5036172015.PubMed/NCBI
43	Trauzold A, Röder C, Sipos B, Karsten K, Arlt A, Jiang P, Martin-Subero JI, Siegmund D, Müerköster S, Pagerols-Raluy L, et al: CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J. 19:620–622. 2005. View Article : Google Scholar : PubMed/NCBI
44	Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, et al: Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res. 11:440–449. 2005.PubMed/NCBI
45	Stipa F, Lucandri G, Limiti MR, Bartolucci P, Cavallini M, Di Carlo V, D'Amato A, Ribotta G and Stipa S: Angiogenesis as a prognostic indicator in pancreatic ductal adenocarcinoma. Anticancer Res. 22:445–449. 2002.PubMed/NCBI
46	Benckert C, Thelen A, Cramer T, Weichert W, Gaebelein G, Gessner R and Jonas S: Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer. Surg Today. 42:169–176. 2012. View Article : Google Scholar : PubMed/NCBI
47	Amin Z, Theis B, Russell RC, House C, Novelli M and Lees WR: Diagnosing pancreatic cancer: The role of percutaneous biopsy and CT. Clin Radiol. 61:996–1002. 2006. View Article : Google Scholar : PubMed/NCBI
48	Annese T, Tamma R, Ruggieri S and Ribatti D: Angiogenesis in pancreatic cancer: Pre-clinical and clinical studies. Cancers (Basel). 11:3812019. View Article : Google Scholar
49	Zhang Z, Ji S, Zhang B, Liu J, Qin Y, Xu J and Yu X: Role of angiogenesis in pancreatic cancer biology and therapy. Biomed Pharmacother. 108:1135–1140. 2018. View Article : Google Scholar : PubMed/NCBI
50	Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill RA, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM and Guha S: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer. 125:1027–1037. 2009. View Article : Google Scholar : PubMed/NCBI
51	Yang HL, Chang HC, Lin SW, Kumar KJS, Liao CH, Wang HM, Lin KY and Hseu YC: Antrodia salmonea inhibits TNF-α-induced angiogenesis and atherogenesis in human endothelial cells through the down-regulation of NF-κB and up-regulation of Nrf2 signaling pathways. J Ethnopharmacol. 151:394–406. 2014. View Article : Google Scholar : PubMed/NCBI